Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome | MDCX Stock NewsStockTitan·18 hours agoMDCX-14.00%
Medicus Pharma wins FDA backing for optimized Phase 2 Teverelix study in acute urinary retentionPUBT·Jul 16 at 06:30 AMMDCX-14.00%
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga_article·Jul 13 at 04:05 PMSNWV+2.87%MDCX-14.00%
Medicus Pharma To Highlight SkinJect Phase 2 Data And Teverelix Clinical Advances At BIO 2026benzinga_article·Jun 22 at 07:00 AMMDCX-14.00%
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026 | MDCX Stock NewsStockTitan·Jun 21 at 10:30 PMMDCX-14.00%
U.S. stock night market fluctuations: MDCX rose 12.63% in night trading with no positive news, increased volatility awaits resolutionPrice Alert·Jun 21 at 07:56 PMMDCX-14.00%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Jun 18 at 12:06 PMATPC-1.63%APLM-1.15%
